Amylin Pharmaceuticals Inc. and Eli Lilly and Co. are calling it quits after a nearly decade-long collaboration on diabetes drug exenatide, a move that leaves Amylin positioned as a potentially hot takeover candidate, especially if the once-weekly version of the glucagon-like peptide-1 receptor agonist, Bydureon, finally clears FDA hurdles early next year.